Repare Therapeutics Inc. RPTX 深 沪
等待开盘 03-27 09:30:00 美东时间
2.65
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.65
- 总市值 11.10万
- 52周最高 2.66
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.89
- 委 比 0.00%
- 总股本 4.19万
- 历史最高 46.44
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.89
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Repare Therapeutics Receive Shareholders Approval Of Its Acquisition By XenoTherapeutics
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued
01-17 06:01
Market-Moving News for December 24th
PATH: 8% | UiPath To Replace Synovus Financial In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Friday, January 2; Versant Media Group To Replace Brandywine Realty Trust In The S&P Smallcap
2025-12-24 20:20
Repare Therapeutics Sells Cancer Drug Asset To Gilead For Up To $30M
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's
2025-12-24 20:19
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
RAPT Therapeutics appoints Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors, adding expertise to advance RPT904, a monoclonal antibody for allergic diseases, through Phase 2 trials in CSU, asthma, and food allergy.
2025-06-23 12:00
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
RAPT Therapeutics将实施1:8反向股票拆分，于6月16日生效，17日起以新CUSIP号交易。此举将流通股数由约1.323亿降至1650万，影响股票期权、warrants及激励计划。
2025-06-13 13:00
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
Radiopharm Theranostics' RAD101 has received FDA Fast Track Designation to differentiate between recurrent brain metastases and treatment effects in a Phase 2 clinical trial.
2025-06-11 12:00
RAPT Therapeutics to Participate in Upcoming Investor Conferences
RAPT Therapeutics announced that its management team will participate in two investor conferences in June: the Goldman Sachs Global Healthcare Conference on June 10 and the UBS Biotech Conference on June 24.
2025-06-04 20:05
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
The Phase 2a trial of Rapport Therapeutics' RAP-219 for refractory focal epilepsy is fully enrolled, with topline results expected in September 2025. The company highlighted the drug's potential in epilepsy, bipolar mania, and neuropathic pain during its investor day and has sufficient funds through 2026.
2025-06-02 18:45
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
Rapport Therapeutics announced that its management will participate in two upcoming investor conferences: the Jefferies Global Healthcare Conference in New York City on June 4 and the Goldman Sachs Global Healthcare Conference in Miami on June 9.
2025-05-27 11:00
Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2025-03-07 22:04
